CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)
(the "**Company**")

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE LISTING MANUAL

Pursuant to Rule 706A of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"), the board of directors (the "**Board**") of Clearbridge Health Limited (the "**Company**") wishes to announce the following transactions that occurred during the six-month financial period from 1 July 2021 to 31 December 2021.

INCORPORATION OF SUBSIDIARY IN SINGAPORE

On 20 September 2021, the Company's wholly-owned subsidiary, Clearbridge Assays Pte. Ltd. had incorporated a wholly-owned subsidiary in Singapore known as Renum Distribution Holdings Pte. Ltd. ("**RDHPL**") (the "**Incorporation**").

RDHPL has an issued share capital of S$1,000 and its principal activity is investment holding.

On 23 September 2021, SAM Laboratory Pte. Ltd., a wholly-owned subsidiary of the Company, had transferred 300,000,000 ordinary shares in Clearbridge Medical Asia Pte. Ltd. ("**CBMAPL**"), representing the entire issued and paid-up capital of CBMAPL to RDHPL for a consideration of S$1.00.

The Incorporation was funded through internal resources and it is not expected to have any material impact on the net tangible assets and earning per shares of the Group for the financial year ended 31 December 2021.

None of the Directors or controlling shareholders of the Company and their respective associates has any interest, direct or indirect, in the Incorporation, save for their shareholdings in the Company, if any.

Please also refer to the Company's announcement dated 13 August 2021 for transaction(s) that occurred during the half year ended 30 June 2021.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

28 February 2022

---

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*